In this monologue, a muscle biologist and longevity trialist explains how diabetes drugs that act as GLP‑1 agonists (e.g., Ozempic) have been repurposed for obesity treatment. Clinical trials show a 10‑15% body‑weight reduction over 12‑18 months, driven largely by a 10% loss of fat mass. However, the speaker highlights a less‑discussed side effect: a 5% loss of total weight comes from muscle loss—equivalent to 5‑10 pounds or more, which mirrors a decade’s worth of age‑related muscle decline in a single year. The most common adverse events reported in New England Journal of Medicine studies are nausea and gastrointestinal issues. While the drugs are effective for reducing obesity‑related cardiovascular risk, the rapid muscle loss raises concerns for long‑term health and longevity.
Chapters
These were classically developed as diabetes medications. Right. These were the new stars in managing diabetes. And what they found was that they had this specific, as you said, is the peptides that block sort of the GLP1 glucagon stimulation. And that basically allowed people to start researching on their obesity effects. And they were such. The trials showed some very striking clinical evidence. And there's a big buzz and a big craze now around these drugs. And I think what has been sort of buried and shadowed in all the hype around most of these drugs, if you look at the trials, cause about a 10 to 15% weight loss in about 12 to 18 months time span. Right. Is the side effects. And the most common, if you look up all these New England Journal Medicine articles around these trials is as you said, nausea and sort of GI issues that accompany them. But that's one side of the thing. The main reason I'm here today is sort of. I'm a muscle biologist and a longevity trialist and we have been studying muscle decline with the aging process. Right. And you lose. We've been saying that, and We've been studying 1% of muscle every year after your third, fourth decade of life. What they saw in these trials with Ozempic was that in addition to, you know, the fifth out of that 15% weight loss was 10% fat, which is great. You know, so they are great drugs because they're going to help a certain section of the population that is, that is obese and is being obese is making them prone to cardiovascular diseases, obviously another chronic diseases. But you're also losing 5% of that weight loss is the muscle loss. And that 5% is about 5 to 10 pounds or even more in certain cases. So that's what, you know, for me as a, as a muscle scientist and the trialist was something very concerning because you're losing almost what you're supposed to lose in 10 years in about one year with these drugs.
